SCHEMBL13638580

SCHEMBL13638580

C=C1CC(Nc2nccc(-c3ccc(CCC(=O)c4ccccc4)s3)n2)CC(C)(C)N1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 7/20 0.35
CHUK O15111 6/20 0.35
IKBKG Q9Y6K9 6/20 0.35
AKT3 Q9Y243 2/20 0.35
AURKA O14965 1/20 0.34
TTK P33981 1/20 0.34
AURKB Q96GD4 1/20 0.34
INCENP Q9NQS7 1/20 0.34
MAPK8 P45983 4/20 0.34
MAPK14 Q16539 1/20 0.34
HDAC8 Q9BY41 2/20 0.33
HDAC6 Q9UBN7 2/20 0.33
JUN P05412 3/20 0.33
MAPK9 P45984 3/20 0.33
MAPK10 P53779 2/20 0.33
CDK2 P24941 2/20 0.33
HPGD P15428 1/20 0.32
RAB9A P51151 1/20 0.32
GSK3B P49841 1/20 0.32
TEC P42680 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13638578 0.88 IKBKB (0.37) IKBKBCHUKIKBKGAKT3MAPK8
SCHEMBL4495433 0.88 EZH2 (0.38) IKBKBCHUKIKBKGAKT3AURKA
SCHEMBL13638522 0.88 IKBKB (0.36) IKBKBCHUKIKBKGAKT3MAPK8
SCHEMBL13638432 0.85 IKBKB (0.39) IKBKBCHUKIKBKGAKT3MAPK8
SCHEMBL13638429 0.84 IKBKB (0.34) IKBKBCHUKIKBKGAKT3AURKA
SCHEMBL13638430 0.84 AKT3 (0.36) IKBKBCHUKIKBKGAKT3MAPK8
SCHEMBL13638303 0.84 IKBKB (0.43) IKBKBCHUKIKBKGAKT3CDK2
SCHEMBL13638292 0.84 KDR (0.37) IKBKBCHUKIKBKGAKT3CDK2
SCHEMBL13638579 0.84 SRC (0.35) IKBKBCHUKIKBKGAKT3MAPK8
SCHEMBL13638675 0.82 CDK4 (0.33) IKBKBCHUKIKBKGAKT3CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK IKBKB 2/4885CHUK 3/4885IKBKG 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.